CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy

Table 3 CD133 expression according to the clinicopathologic parameters in CRC patients

	All patients (N=271)	CD133 IHC expression (0)	CD133 IHC expression (1-10%)	CD133 IHC expression (11-50%)	CD133 IHC expression (51-100%)
Variables	N	%	%	%	%
Gender
Male	161	27.95	23.60	22.98	25.46
Female	110	32.72	20.00	20.00	27.27
Tumor site*
Colon	150	37.33	22.66	17.33	17.33
Rectum	121	20.66	21.48	27.27	30.57
pTNM stage
II	122	31.14	25.40	22.13	21.31
III	149	28.85	19.46	21.47	30.20
pT stage
T1	4	75.00	0	0	25.00
T2	6	16.66	66.66	16.66	0
T3	239	29.70	21.75	22.17	26.35
T4	22	27.27	18.18	22.72	31.81
pN stage
N0	123	30.90	25.20	21.95	21.95
N1	88	29.54	17.04	25.00	28.40
N2	56	26.78	25.00	17.85	30.35
N3	4	50.00	0	0	50.00
Histologic differentiation*
Well	16	37.50	31.25	18.57	12.50
Moderate	225	25.33	22.22	22.66	29.77
Poor	15	53.33	20	26.66	0
Mucinous adenocarcinoma	15	66.66	13.33	6.66	13.33
Adjuvant therapy
Yes	171	28.07	22.22	18.71	30.99
No	100	33.00	22.00	27.00	18.00

ISSN: 1471-2407